Journal of Commercial Biotechnology welcomes new editorial advisory board members

Nov. 29, 2011 - PRLog -- The Journal of Commercial Biotechnology is proud to announce the addition of two esteemed industry experts to its advisory board.

The new editorial board members are:

- Ananda Mohan Chakrabarty, distinguished university professor at the University of Illinois at Chicago and noted for his genetically modified Pseudomonas bacteria that became the first genetically-engineered organism to gain a US patent as a result of the Supreme Court decision in Diamond vs. Chakrabarty. He is the co-founder of two companies, CDG Therapeutics Inc. in Chicago and Amrita Therapeutics in India.

- Meir Perez Pugatch, Managing Director Pugatch Consilium; Chair, Division of Health Systems Administration, School of Public Health, University of Haifa, Israel

These esteemed individuals complement the existing editorial advisory board ( http://commercialbiotechnology.com/about/editorialTeam ), which includes:

- Mark Ahn, Principal, Pukana Partners, Ltd., USA, United States
- John Avellanet, Cerulean Associates LLC, United States
- Boris Bogdan, Partner, Avance, Basel GmbH, Switzerland
- Arthur Boni, John R. Thorne Chair of Entrepreneurship; Associate Teaching Professor of Entrepreneurship; and Director, Donald H. Jones Center for Entrepreneurship, Tepper School of Business, Carnegie Mellon University, United States
- Walter Bratic, Managing Director, Overmont Consulting LLC, United States
- G. Steven Burrill, Chief Executive Officer, Burrill & Company, United States
- Steven Casper, Henry E. Riggs Professor of Management, Keck Graduate Institute of Applied Life Sciences, United States
- Vijay Chandra, Chairman & CEO, Strand Life Sciences Pvt Ltd, India and Consulting Professor, ISL/EE, Stanford University, United States
- James Class, Director, Global Public Policy, Merck, United States
- Jeremy Laurence Curnock Cook, Executive Chairman, Bioscience Managers Limited, United Kingdom
- Iraj Daizadeh, Senior Manager, Amgen Inc, United States
- Mitch DeKoven, Director - Reimbursement and Market Access, Health Economics & Outcomes Research, IMS Health, United States
- Spencer G. Feldman, Shareholder, Greenberg Traurig, United States
- Sharon Finch, Director, Medius Associates, United Kingdom
- Hernan Garrido-Lecca, Chairman and CEO Bioinvest; Professor of Economics and Public Policy, Universidad de San Martín de Porres, Lima Peru and Former Minister of Health, Peru
- Gerald S. Graham, Business and Management Consultant, Graham Consulting Group, United States
- Dave Jensen, Managing Director, CareerTrax Inc., United States
- Kenneth Kaitin, Director, Tufts Center for the Study of Drug Development and Professor of Medicine, Tufts University School of Medicine, United States
- John Khong, Owner, Niche Medical, J & M Technologies, Cell Sciences; Adjunct faculty, LKC Business School, Singapore management University, Singapore
- Edward L. Korwek, Partner, Hogan Lovells, United States
- Thomas J. Kowalski, Attorney at Law, Vedder Price P.C., United States
- Leonard Lerer, Sudarskis & Partners, United Arab Emirates
- Weijun Li, Senior Research Scientist, Global Biological Development, Bayer HealthCare Pharmaceuticals, United States
- Bryan A. Liang, Professor of Anesthesiology & Director San Diego Center for Patient Safety, University of California San Diego School of Medicine; Professor of Law & Executive Director, Institute of Health Law Studies, California Western School of Law, United States
- Kate Lynch, CEO, Generic Medicines Industry Association (GMiA), Australia
- Barry Marenberg, Chief Intellectual Property Strategist, BJM BioPat Solutions, United States
- Henry I. Miller, Senior Research Fellow of Scientific Philosophy & Public Policy, Hoover Institution, Stanford University, United States
- Stefan Michael Miller, Associate, Dechert LLP, United States
- Sudha Nair, Director, Global Business Development, Apotex Fermentation Inc., Canada
- Robin Nott, Chair of the Laws Committee, Licensing Executives Society Britain and Ireland, United Kingdom
- Meir Perez Pugatch, Chair Division of Health Systems Administration, School of Public Health, University of Haifa; Managing Director Pugatch Consilium, Israel
- Rebecca Robins, Director, Europe, Business Development, Interbrand Wood Healthcare, United Kingdom
- Anthony J Russo, Chairman and CEO, Russo Partners, United States
- Stephen M. Sammut, Senior Fellow, Wharton Health Care Systems and Entrepreneurial Programs and Venture Partner, Burrill & Company, United States
- Simon Shohet, Practice Director, Pope Woodhead & Associates Ltd, United Kingdom
- Grant Skrepenk, Assistant Professor, The University of Arizona College of Pharmacy and Investigator, Center for Health Outcomes and PharmacoEconomic Research, United States
- Anthony Stevens, Director, Medical Options, United Kingdom
- Philip Neal Sussman, Managing Partner, The Channel Group LLC, United States
- Michael Vitale, Director of Commercialisation, Monash Asia-Pacific Centre for Science and Wealth Creation, Monash University, Australia
- Stan Yakatan, Chairman, Katan Associates, United States

For more information, see the Journal of Commercial Biotechnology at http://CommercialBiotechnology.com

# # #

The Journal of Commercial Biotechnology is a quarterly peer-reviewed professional journal which focuses on the commercial, legal, and regulatory issues affecting biotechnology, biopharmaceutical, agrochemical, and environmental companies.